Zenitar
赜灵生物
Zenitar is a Chengdu-based biopharmaceutical company, known formally as 成都赜灵生物医药科技有限公司 (Zai Ling Bio). It raised nearly RMB 400 million in a Series B+ round led by Qiming Venture Partners in August 2025, with participation from Gaorong Capital, Jifeng Capital, Qiji Investment, 5Y Capital, and Zhongyuan Investment . By January 2026, it had closed a nearly RMB 600 million Series C co-led by True Light Capital (淡明资本), a Temasek subsidiary, and Qiming Venture Partners, with Tencent Investment, BlueRun Ventures, and others joining . The company does not appear in Linear Capital's disclosed portfolio, which focuses on data intelligence and frontier technology applications such as Horizon Robotics, Rokid, and AgiBot .
AI-generated — may contain errors, please verify.
Coverage
New Forces Keep Coming｜5Y News Monthly
The big news from last month.
五源资本·5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
五源资本·Compile Uncertainty into Answers | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
五源资本·
